In-vitro susceptibility of cefiderocol and other comparators in carbapenem-resistant Gram-negative bacilli: A study from India.

IF 1.4 4区医学 Q4 IMMUNOLOGY Indian Journal of Medical Microbiology Pub Date : 2025-01-31 DOI:10.1016/j.ijmmb.2025.100793

Akansha Didwania, Sarita Mohapatra, Deepak Kocher, Hitender Gautam, Priyanka Kumari, Arvind Kumar, Manish Soneja, Naval K Vikram, Seema Sood, Benu Dhawan, Bimal Kumar Das, Rama Chaudhry, Manoranjan Mahapatra, Naveet Wig, Arti Kapil

{"title":"In-vitro susceptibility of cefiderocol and other comparators in carbapenem-resistant Gram-negative bacilli: A study from India.","authors":"Akansha Didwania, Sarita Mohapatra, Deepak Kocher, Hitender Gautam, Priyanka Kumari, Arvind Kumar, Manish Soneja, Naval K Vikram, Seema Sood, Benu Dhawan, Bimal Kumar Das, Rama Chaudhry, Manoranjan Mahapatra, Naveet Wig, Arti Kapil","doi":"10.1016/j.ijmmb.2025.100793","DOIUrl":null,"url":null,"abstract":"Introduction: Cefiderocol is a parenteral catechol-type siderophore cephalosporin, which has been approved for the treatment of Gram-negative bacterial infections. Its activity among the carbapenem-resistant Gram-negative bacilli (CR-GNBs) in India is largely unknown.Methodology: We tested in-vitro susceptibility of cefiderocol in 84 CR-GNB [ carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant Escherichia coli (CREC) and carbapenem-resistant Klebsiella pneumoniae (CRKP)] by broth microdilution (BMD) and disc diffusion (DD) using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints and concordance of DD was compared with BMD. Cefiderocol susceptibility was evaluated based on the presence of blaNDM and blaOXA-48 genes.Results: Following CLSI and EUCAST breakpoints, 76.2% [CRKP: 95.65% (22/23); CRPA: 80% (16/20); CREC: 65% (13/20); CRAB: 61.9% (13/21)] and 52.3% [ CRKP: 82.6% (19/23); CRPA: 50% (10/20); CREC: 20% (4/20)] of CR-GNBs were observed susceptible to cefiderocol, respectively. The susceptibility to cefiderocol was seen higher with lower MIC50 and MIC90 values for CRKP [1 μg/ml; 4 μg/ml ] and CRPA [2 μg/ml; 8 μg/ml ] in comparison to the other two groups of organisms. The categorical agreement between BMD and DD was found between 90% and 100% for all organisms. Cefiderocol susceptibility among the isolates harbouring blaNDM, blaOXA-48, and both blaNDM and blaOXA-48 genes was observed 75% (24/32); 100% (3/3); and 66.6% (4/6), respectively.Conclusion: Cefiderocol demonstrated high in-vitro activity against CRKP and CRPA isolates from India with lower MIC50 and MIC90 irrespective of the presence of blaNDM and blaOXA-48 genes.","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":" ","pages":"100793"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijmmb.2025.100793","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cefiderocol is a parenteral catechol-type siderophore cephalosporin, which has been approved for the treatment of Gram-negative bacterial infections. Its activity among the carbapenem-resistant Gram-negative bacilli (CR-GNBs) in India is largely unknown.

Methodology: We tested in-vitro susceptibility of cefiderocol in 84 CR-GNB [ carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant Escherichia coli (CREC) and carbapenem-resistant Klebsiella pneumoniae (CRKP)] by broth microdilution (BMD) and disc diffusion (DD) using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints and concordance of DD was compared with BMD. Cefiderocol susceptibility was evaluated based on the presence of bla_NDM and bla_OXA-48 genes.

Results: Following CLSI and EUCAST breakpoints, 76.2% [CRKP: 95.65% (22/23); CRPA: 80% (16/20); CREC: 65% (13/20); CRAB: 61.9% (13/21)] and 52.3% [ CRKP: 82.6% (19/23); CRPA: 50% (10/20); CREC: 20% (4/20)] of CR-GNBs were observed susceptible to cefiderocol, respectively. The susceptibility to cefiderocol was seen higher with lower MIC₅₀ and MIC₉₀ values for CRKP [1 μg/ml; 4 μg/ml ] and CRPA [2 μg/ml; 8 μg/ml ] in comparison to the other two groups of organisms. The categorical agreement between BMD and DD was found between 90% and 100% for all organisms. Cefiderocol susceptibility among the isolates harbouring bla_NDM, bla_OXA-48, and both bla_NDM and bla_OXA-48 genes was observed 75% (24/32); 100% (3/3); and 66.6% (4/6), respectively.

Conclusion: Cefiderocol demonstrated high in-vitro activity against CRKP and CRPA isolates from India with lower MIC₅₀ and MIC₉₀ irrespective of the presence of bla_NDM and bla_OXA-48 genes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Indian Journal of Medical Microbiology IMMUNOLOGY-

CiteScore

2.20

自引率

0.00%

发文量

154

审稿时长

73 days

期刊介绍： Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study. Review articles, Special Articles or Guest Editorials are accepted on invitation.